After the first 6 months of disease-modifying antirheumatic drugs (DMARDs) use in patients with rheumatoid arthritis (RA), most very abnormal results newly seen in long-term routine laboratory ...
GRAPPA published treatment recommendations for PsA in 2009 based on evidence from systematic reviews and consensus of 70 rheumatologists and dermatologists with subspecialty expertise in management of ...
A scoping review published in Arthritis Care & Research compares existing recommendations for the use of disease-modifying anti-rheumatic drugs (DMARDs) in pregnancy and reproductive health for women ...
Patients with Medicare Part D insurance plans experience uneven and “restrictive” coverage of certain drugs and drug classes ...
Patients with psoriatic arthritis who received bDMARDs vs cDMARDs had a lower risk for major adverse cardiovascular events, all-cause mortality, and cardiovascular mortality. Biologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results